Publications by authors named "Emma Touizer"

Antigen-specific antibody infusion is known to enhance or suppress germinal center (GC) responses depending on the affinity of the infusion. We hypothesized that infusing monoclonal antibodies (mAbs) of escalating affinity during an immunization regimen may progressively escalate selection pressure on competing B cells, increasing their affinity. To test this, we immunized mice with HIV envelope gp120 and infused CD4 binding-site (CD4bs)-specific mAbs.

View Article and Find Full Text PDF

Immunological determinants favouring emergence of broadly neutralising antibodies are crucial to the development of HIV-1 vaccination strategies. Here, we combined RNAseq and B cell cloning approaches to isolate a broadly neutralising antibody (bnAb) ELC07 from an individual living with untreated HIV-1. Using single particle cryogenic electron microscopy (cryo-EM), we show that the antibody recognises a conformational epitope at the gp120-gp41 interface.

View Article and Find Full Text PDF
Article Synopsis
  • Natural killer (NK) cell subsets with adaptive properties play a significant role in enhancing vaccine-induced immune responses, particularly against SARS-CoV-2, and exhibit specialization in antibody-dependent functions.
  • In people living with HIV (PLWH), SARS-CoV-2 infection leads to a change in NK cell characteristics, resulting in a more differentiated/adaptive phenotype, which is also observed after vaccination.
  • The study highlights that adaptive NK cells not only contribute to sustained immune responses post-infection but can also enhance the effectiveness of vaccines, suggesting their potential to support immune protection in vulnerable populations like PLWH.
View Article and Find Full Text PDF

Patients with haematological malignancies are more likely to have poor responses to vaccination. Here we provide detailed analysis of the humoral and cellular responses to COVID-19 vaccination in 69 patients with B-cell malignancies. Measurement of anti-spike IgG in serum demonstrated a low seroconversion rate with 27.

View Article and Find Full Text PDF

We assessed a cohort of people living with human immunodeficiency virus (PLWH) (n = 110) and HIV negative controls (n = 64) after 1, 2 or 3 SARS-CoV-2 vaccine doses. At all timepoints, PLWH had significantly lower neutralizing antibody (nAb) titers than HIV-negative controls. We also observed a delayed development of neutralization in PLWH that was underpinned by a reduced frequency of spike-specific memory B cells (MBCs).

View Article and Find Full Text PDF

People living with HIV (PLWH) on suppressive antiretroviral therapy (ART) can have residual immune dysfunction and often display poorer responses to vaccination. We assessed in a cohort of PLWH (n=110) and HIV negative controls (n=64) the humoral and spike-specific B-cell responses following 1, 2 or 3 SARS-CoV-2 vaccine doses. PLWH had significantly lower neutralizing antibody (nAb) titers than HIV-negative controls at all studied timepoints.

View Article and Find Full Text PDF
Article Synopsis
  • There is an urgent need to understand how people living with HIV respond to SARS-CoV-2 to improve their health strategies.
  • Most individuals with well-managed HIV can still mount a strong immune response to SARS-CoV-2, with similar humoral and T cell responses as those without HIV.
  • The effectiveness of T cell responses in HIV-positive individuals is influenced by their CD4 T cell levels, suggesting that insufficient immune recovery could impact their ability to fight off infections and respond to vaccines.
View Article and Find Full Text PDF

Although two-dose mRNA vaccination provides excellent protection against SARS-CoV-2, there is little information about vaccine efficacy against variants of concern (VOC) in individuals above eighty years of age. Here we analysed immune responses following vaccination with the BNT162b2 mRNA vaccine in elderly participants and younger healthcare workers. Serum neutralization and levels of binding IgG or IgA after the first vaccine dose were lower in older individuals, with a marked drop in participants over eighty years old.

View Article and Find Full Text PDF
Article Synopsis
  • There is a critical need to study how people living with HIV (PLWH) respond immune-wise to SARS-CoV-2 to help manage their health risks.
  • Most PLWH on antiretroviral therapy (ART) develop functional immune responses to the virus, with similar humoral and T cell responses as those without HIV, lasting for 5-7 months.
  • The strength of these responses is influenced by factors like the size of naive CD4 T cell pools, suggesting that how well immune systems recover on ART may affect vaccine effectiveness and individual health management during COVID-19.
View Article and Find Full Text PDF
Article Synopsis
  • There is a critical need to understand immune responses to SARS-CoV-2 in people living with HIV (PLWH) to improve risk management strategies, especially since some PLWH may still experience immune deficiencies despite treatment.
  • A study compared the immune responses of PLWH on antiretroviral therapy (ART) to those of HIV-negative individuals after mild COVID-19, finding that both groups developed comparable levels of antibodies and T cell responses against the virus.
  • However, the immune response in PLWH was influenced by their CD4:CD8 ratio and the size of their naive CD4 T cell pool, which may impact their long-term immunity and the effectiveness of vaccination efforts against SARS-CoV-2.
View Article and Find Full Text PDF

With an estimated three to five million human cases annually and the potential to infect domestic and wild animal populations, influenza viruses are one of the greatest health and economic burdens to our society, and pose an ongoing threat of large-scale pandemics. Despite our knowledge of many important aspects of influenza virus biology, there is still much to learn about how influenza viruses replicate in infected cells, for instance, how they use entry receptors or exploit host cell trafficking pathways. These gaps in our knowledge are due, in part, to the difficulty of directly observing viruses in living cells.

View Article and Find Full Text PDF

Detection of viral DNA by cyclic GMP-AMP synthase (cGAS) is a first line of defence leading to the production of type I interferon (IFN). As HIV-1 replication is not a strong inducer of IFN, we hypothesised that an intact capsid physically cloaks viral DNA from cGAS. To test this, we generated defective viral particles by treatment with HIV-1 protease inhibitors or by genetic manipulation of gag.

View Article and Find Full Text PDF
Article Synopsis
  • The immune system uses checkpoint pathways to manage responses, prevent autoimmunity, and regulate overall immune function, but cancer cells can exploit these pathways to evade immune detection and thrive.
  • Blocking antibodies targeting molecules like CTLA-4 and PD-1/PD-L1 can enhance immune responses against tumors, leading to significant success in melanoma treatment, although not every patient benefits and some may develop resistance.
  • Research is ongoing to explore combination therapies using existing and new checkpoint inhibitors (like A2AR, LAG-3, and IDO) to improve patient outcomes and survival rates compared to single-agent treatments.
View Article and Find Full Text PDF